RE: Seller cleared17 Mar 2021 15:27
It had a £300m Mcap at that level, so current Mcap been only £20m definitely allows for a 10 bagged ahead of readout. The fact they have a US partner fully funding the trial is extremely important where the FDA are concerned, also targeting those Lupus patients with antibodies who best respond to the drug which accounts for 70 percent of all Lupus patients so the results should be extremely good and if this is the case I would argue a £500m Mcap for a Lupus drug that has a positive phase 3 that meets clinical end points and gets FDA approval for use should be cheap. IMM could then agree licence deals with the rest of the world sit back and make a fortune or me bought out by big pharma. Definitely has huge potential this one, life changing if they get it right, FDA meeting in next few weeks will be key